Genetic biomarker linked to improved survival for patients with certain brain tumors
Share

VIDEO: In a new study at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, experts found that survival among patients… view more 

view more 

A DNA-level biomarker (MGMT promoter methylation) can be used to help predict survival outcomes in patients with high-risk, low-grade gliomas, according to a new study conducted through the NRG Oncology/RTOG collaborative clinical trials group and led by scientists at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute (OSUCCC – James).

New data reported in the June 28, 2018, issue of the medical journal JAMA Oncology shows that patients with MGMT methylated tumors are more than twice as likely to survive after combination temozolomide and radiation treatment than patients with unmethylated tumors.

Gliomas are a class of brain tumors that develop in the supportive cells that surround nerve cells in the brain.

Study Methods and Results

Previously reported findings from the NRG Oncology/RTOG 0424 clinical trial report a three-year overall survival benefit for certain brain tumor patients who receive the drug temozolomide in addition to radiation therapy compared with the standard of care. Data regarding the significance

read more...


Article originally posted at
www.eurekalert.org

Click here for the full story


CategoryAggregator News

© 2017 - LIFE EXTENSION ADVOCACY FOUNDATION
Privacy Policy / Terms Of Use

Powered by MMD